CLN-619 demonstrated monotherapy activity across a range of tumor types, including in patients whose cancer had progressed on checkpoint inhibitor...
Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double...
Triplet of ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with metastatic BRAF V600E-mutated colorectal cancer...
As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression,...
New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Conference call and webcast scheduled on...
vTv discovered small molecule RAGE inhibitor being developed by Cantex under worldwide development and commercialization agreementHIGH POINT, N.C., May 24,...
Presidential Plenary Lecture to be Presented Wednesday, May 31 at the ICST Opening SessionBOCA RATON, Fla., May 24, 2023 (GLOBE NEWSWIRE) --...
The Foundation will use H1’s Trial Landscape solution to streamline communication with physicians treating Parkinson’s, improve representation in clinical studies,...
DURHAM, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life...
Company approaching Phase 2 topline data readout for prevention of post-surgical abdominal adhesions Continued momentum with execution of ongoing dose...
NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
TORONTO, May 23, 2023 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), the premier provider of unified eClinical solutions and services...
– Results from the completed Collaborative Health Research Projects (CHRP) study with McMaster University presented at the American Thoracic Society...
WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin...
Pamela Bush, Chief Business Officer of Predictive Oncology, to discuss advancing pipelines and using patient heterogeneity with AI to solve...
Builds on Celularity’s December 2022 announcement of Halal Certification of its commercial-stage biomaterial products, and clinical and investigational stage cellular...
Filed FDA submission for T2Biothreat Panel, implemented a restructuring program and announced exploration of strategic alternativesLEXINGTON, Mass., May 23, 2023...
Latest patent broadens protection around OCEA’s platform of first-in-class anti-CHi3L1 therapeutic immunotherapy candidates, based on the breakthrough discovery by scientific...
NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m. ETNAARDEN, the Netherlands and MIAMI,...